23 October 2015 - Amgen today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending that Imlygic (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

For more details, go to: http://www.amgen.com/media/news-releases/2015/10/amgen-receives-chmp-positive-opinion-for-imlygic-talimogene-laherparepvec/